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Cathelicidin LL-37: An Antimicrobial Peptide with a 
Role in Inflammatory Skin Disease
Markus Reinholz, M.D., Thomas Ruzicka, M.D., Jürgen Schauber, M.D.
Department of Dermatology and Allergy, Ludwig-Maximilian-University, Munich, Germany
Chronic inflammatory skin diseases such as atopic 
dermatitis, psoriasis or rosacea are very common. Although 
their exact pathogenesis is not completely understood all 
three diseases are characterized by dysregulation of cuta-
neous innate immunity. Cathelicidin LL-37 is an important 
effector molecule of innate immunity in the skin and atopic 
dermatitis, psoriasis or rosacea show defects in cathelicidin 
expression, function or processing. In atopic dermatitis, 
cathelicidin induction might be disturbed resulting in 
defective antimicrobial barrier function. In contrast, psori-
asis is characterized by overexpression of cathelicidin. 
However to date it is unclear whether pro- or anti- 
inflammatory functions of cathelicidin predominate in 
lesional skin in psoriasis. In rosacea, cathelicidin processing 
is disturbed resulting in peptide fragments causing infla-
mmation, erythema and telangiectasias. In this review, the 
current evidence on the role of cathelicidin LL-37 in the 
pathogenesis of inflammatory skin diseases will be outlined. 
As cathelicidin LL-37 might also serve as a future treatment 
target potential novel treatment strategies for those diseases 
will be discussed. (Ann Dermatol 24(2) 126∼135, 2012)
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THE SKIN: AN INNATE IMMUNE ORGAN
Our skin is the first barrier against the outside environ-
ment. In order to provide an efficient defense the skin is 
equipped with various innate mechanisms against 
invading microbial pathogens. Most do not require the 
specific recognition of the invading pathogen and within 
cutaneous innate immunity three distinct barriers can be 
identified: a chemical, a physical and a cellular barrier. 
While a low pH and small cationic peptides with 
antimicrobial activity contribute to the chemical shield on 
the surface of the skin, the stratum corneum forms the 
initial physical barrier. Epidermal keratinocytes form the 
first cellular barrier against infectious agents
1. These cells 
together with professional antigen presenting cells such as 
dendritic cells and dermal macrophages form the first line 
of cellular innate immunity in the skin. All these cells are 
equipped with sensors and communicate with each other 
upon microbial challenge or a danger signal. Subsequently, 
further immune or pro-inflammatory cascades are triggered 
providing an adequate and coordinated immune response.
ANTIMICROBIAL PEPTIDES (AMPs): 
ESSENTIAL PLAYERS IN CUTANEOUS 
INNATE IMMUNITY
Among the soluble factors secreted onto the cutaneous 
surface AMPs play a particularly important role in innate 
immunity. AMPs are evolutionary well-conserved gene- 
encoded, short (＜100 amino acids), amphipathic molecules 
with hydrophobic and cationic amino acids arranged 
spatially
2. AMPs form predominantly two different secon-
dary structures, disulfide-rich peptides form beta-sheets 
while linear peptides form alpha-helices
3. Their amphi-
pathic structure allows those peptides to be soluble in 
aqueous environments but also to interact with lipid 
membranes
3. Initially, AMPs were identified as endo-Cathelicidin LL-37 and Inflammatory Skin Disease
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genous antibiotics due to their potential to kill various 
pathogens by disrupting their membranes. They have 
broad spectrum antimicrobial activity and are able to kill 
gram-positive and gram-negative bacteria, viruses and 
fungi
4. Keratinocytes and other resident cells in the skin 
such as eccrine gland cells, mast cells and sebocytes 
produce and secrete AMPs. In addition, invading immune 
cells (e.g. neutrophils, natural killer cells) contribute to the 
pool of AMPs in the skin
4-8.
Resident and infiltrating cells synthesize an impressive 
array of AMPs and to date several hundred of different 
peptides with antimicrobial function have been identified 
in human skin
9-11. Interestingly, many AMPs were first 
characterized for other biological activities and their 
antimicrobial function was later identified. As an example 
the leukocyte protease inhibitor - also known as α- 
melanocyte stimulating hormone - exerts antimicrobial 
activity when tested in culture
9.
Importantly, the production of AMPs in the skin is a 
dynamic defense mechanism: While some AMPs are 
expressed constitutively in the skin, the production of 
others is highly increased in danger situations such as skin 
injury or infections
12-15. Furthermore, the expression and 
function of AMPs are regulated on the transcriptional and 
post-transcriptional level. Most AMPs are synthesized as 
pro-peptides and activated after proteolytic cleavage from 
their precursor molecules
16,17. Consequently, induction of 
transcription and increased processing are needed to 
provide the skin with enhanced AMP activity.
Two important and well-studied AMP families in human 
skin are the defensins and the cathelicidins
18,19.  β- 
defensin (HBD) 2 was the first skin-derived AMP charac-
terized in man. HBD2 is most effective against gram- 
negative bacteria whereas HBD3 from the same AMP 
family has a broader spectrum of antimicrobial action
13,20. 
HBD2 is induced in skin inflammation and infection
21 and 
Gläser et al.
22 recently showed that HBD2 and 3 are 
inducible by ultraviolet-B (UVB) irradiation as well
23. In 
contrast, HBD1 is constitutively expressed in human skin.
CATHELICIDIN LL-37: AN IMPORTANT AMP 
IN HUMAN SKIN
While there are several gene-encoded defensins, e.g. α- 
and β-defensins, to date only one single cathelicidin gene 
has been identified in man and designated cathelicidin 
antimicrobial peptide (CAMP)
24,25. Like many AMP genes 
CAMP encodes for a pro-peptide which is composed of an 
N-terminal cathelin domain and a C-terminal peptide with 
antimicrobial activity
26. The first active cathelicidin 
identified was LL-37 - a 37 amino acid long peptide with 
broad antimicrobial activity. LL-37 forms an α-helix in 
aqueous solution which enables the peptide to disrupt 
both bacterial membranes and viral envelopes
9. Even 
anti-fungal activity of LL-37 in Candida infections was 
reported
27-29. On the skin surface, active cathelicidin 
peptides such as LL-37 are cleaved from the inactive 
precursor by serine proteases of the kallikrein family
16,19,30. 
As LL-37 gains its antimicrobial activity after cleavage 
from the pro-form processing of cathelicidin by skin 
proteases is an important regulatory mechanism of 
cathelicidin mediated antimicrobial activity. In skin, LL-37 
is synthesized by epithelial cells but also provided by 
infiltrating immune cells such as neutrophils which 
transport LL-37 to infected or wounded skin. In healthy 
skin, cathelicidin expression is barely detected in kera-
tinocytes. In contrast, during infection or injury cathe-
licidin production is strongly induced in these cells
14.
Apart from the antimicrobial activity LL-37 has additional 
functions in the activation and the control of immune 
responses: LL-37 increases cytokine and chemokine 
liberation from local cells and leucocytes and has 
chemotactic effects on a large number of immune cells
4. 
In addition, chemokine and cytokine release is induced by 
LL-37 in mast cells or keratinocytes
31. In cooperation with 
the cytokines LL-37 enhances innate immune responses 
by multiple pathways
4,32. Furthermore, LL-37 enhances 
the proliferation of endothelial cells and influences 
angiogenesis
33. These attributes complement the antimi-
crobial functions of LL-37 and have lead to the perception 
of LL-37 as not only an antimicrobial but an “alarmin”- 
peptide
34.
On a molecular level LL-37 mediates its “alarmin” 
functions on immune or resident cells in a ligand-receptor 
mediated or a receptor-independent manner resulting in 
increased host responses
35. In doing so, LL-37 influences 
adenosine triphosphate-receptor P2X7 and Toll-like 
receptor (TLR) signaling in immune cells, epidermal 
growth factor receptor transactivation or intracellular Ca
2+ 
mobilization
31,36-38.
The dual role of cathelicidin - the antimicrobial and the 
alarmin function - suggests a central role for this peptide in 
cutaneous innate immunity. Consequently, dysfunction of 
the “alarmin”-function of cathelicidin LL-37 could play a 
role of in the pathogenesis of inflammatory skin disease to 
the same extent as impaired antimicrobial activity.M Reinholz, et al
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DYSFUNCTION OF CATHELICIDIN AS A 
CAUSE OF INFLAMMATORY SKIN DISEASE
Emerging evidence suggests that indeed a number of 
inflammatory skin diseases are characterized by dysregulated 
expression or function of cathelicidin peptides. In this 
review, the current knowledge on the role of cathelicidin 
in the pathogenesis of atopic dermatitis (AD), rosacea, 
psoriasis and hidradenitis suppurativa (HS) will be pre-
sented and discussed.
ATOPIC DERMATITIS
AD is a very common inflammatory skin disease with a 
chronic course. Patients suffering from AD show an 
increased susceptibility to infections by viruses, bacteria 
or fungi and have an altered skin microflora
39. A primary 
defense barrier defect caused by structural defects (e.g. 
mutations in the filaggrin gene) or by an immunoglobulin 
E (IgE)-mediated immunonologic disorder with IgE- 
mediated allergic sensitization and an epithelial-barrier 
dysfunction as a consequence of the local inflammation 
are discussed
39.
A deficient innate antimicrobial barrier in AD patients was 
first proposed when an impaired expression of AMPs such 
as cathelicidin and defensins was detected in lesional skin 
in AD
40. In particular, induction of cathelicidin mRNA 
transcription in response to wounding is suppressed in AD 
lesions as compared to healthy skin
41. This could be 
explained by the altered tissue microenvironment in AD 
skin: Th2 cytokines such as interleukin (IL)-4 and IL-, 
which are highly elevated in AD skin, suppress cathe-
licidin induction in keratinocytes
42. As itching is a 
hallmark of AD and scratching results in skin wounding 
failure to upregulate cathelicidin in response to injury 
could decrease the cutaneous antimicrobial activity in AD 
skin
41. 
Furthermore, it has been hypothesized that the increased 
rate of microbial superinfections in AD may be caused by 
reduced AMP expression as a consequence of immuno-
suppressive therapy. In this context, topically applied 
corticosteroids and the calcineurin inhibitor pimecrolimus 
reduce the expression of several AMPs in skin in AD 
compared with healthy controls
43.
In contrast, other groups found enhanced expression of 
cathelicidin LL-37 mRNA and protein expression in 
lesional skin compared with non-lesional skin in AD
44. 
Also, non-lesional skin of atopic and non-atopic children 
shows no significant difference in cathelicidin LL-37 and 
HBD-2 expression
45. Also, the serum levels of cathelicidin 
LL-37 in AD children did not differ from healthy controls 
and increased in subgroups with more severe disease
46. 
Finally, serum LL-37 did not differ between patients with 
or without relevant bacterial superinfection.
Nevertheless, two clinical studies identified subgroups of 
AD patients with severe infectious complications and a 
history of dermatitis herpeticatum in the past, which 
showed defective upregulation of AMPs
47,48.
Hence, the role of cathelicidin LL-37 in the pathogenesis 
of AD is still unclear. Further studies - in particular in 
subgroups of AD patients suffering from severe AD with 
infectious complications - are needed to exactly charac-
terize the role of cathelicidin LL-37 in AD.
ROSACEA
Rosacea is another inflammatory skin disease mainly 
affecting the central portions of the face. The disease often 
affects fair-skinned individuals and shows a chronic 
relapsing course. Rosacea occurs mainly in adults around 
the age of 30 years and typically predominates in 
females
49. The clinical presentations of rosacea include 
erythema and telangiectasias, pustules and erythematous 
papules, rarely nodules or edema. The pathophysiology of 
rosacea is incompletely understood but involves a 
complex interaction of different factors and pathways 
leading to a chronic inflammatory and vascular response.
As cathelicidin LL-37 has pro-inflammatory “alarmin” 
functions and affects vascular growth the expression of 
cathelicidin was investigated in rosacea recently. Indeed, 
cathelicidin is strongly increased lesional skin in rosacea 
compared to the skin of non-affected individuals
50.
As mentioned above, processing of the precursor mole-
cule is a crucial step in activating the different functions of 
cathelicidin peptides. In the skin cathelicidin is processed 
by serine proteases of the kallikrein family (particularly 
kallikrein 5 [stratum corneum tryptic enzyme] and 
kallikrein 7 [stratum corneum chymotryptic enzyme])
16. 
The main resulting peptide is LL-37 - however, LL-37 can 
be processed further to smaller peptide fragments. Also 
these smaller peptide fragments exert immune functions 
but differ in their antimicrobial and immune activating 
capacities
51.
In lesional skin in rosacea the cutaneous protease activity 
is enhanced and increased expression of serine proteases 
such as kallikrein 5 can be observed
50. Furthermore, 
variant cathelicidin peptides and smaller fragments can be 
detected. Thus, in rosacea increased levels of the vasoa-
ctive and inflammatory host-defense peptide LL-37 and its 
proteolytic peptide fragments are found which can be 
explained by an abnormal cathelicidin production and 
pathologic protease activity
50,52.Cathelicidin LL-37 and Inflammatory Skin Disease
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Fig. 1. The role of cathelicidin in the pathogenesis of rosacea and possible therapeutic implications. UV light increases the synthesis 
of vitamin D which induces cathelicidin expression in keratinocytes. ER stress is an alternative inducer of cathelicidin production. 
Increased protease activity in rosacea skin is possibly due to demodex mite colonization: Chitin released from mites triggers TLR2 
receptor activation and increased protease activity. Subsequently, enhanced protease activity leads to increased cleavage of cathelicidin 
LL-37 and further fragments. These fragments trigger inflammation, erythema and telangiectasias. Doxycycline, azelaic acid and retinoids 
mediate their beneficial effects in rosacea possibly by interfering with this pro-inflammatory system through different mechanisms. 
UV: ultraviolet, ER: endoplasmic reticulum, TLR: Toll-like receptor.
Confirming a pathogenic role of cathelicidin in rosacea, 
injection of these peptide fragments found in skin of 
rosacea patients into the skin of mice leads to a 
rosacea-like disease
50. In contrast, the isolated increase of 
protease activity in cathelicidin knock-out mice does not 
cause dermal inflammation
50. 
However, the mechanisms underlying the increased 
cathelicidin production and the enhanced protease acti-
vity in skin of rosacea patients are to date unknown. Both 
seem to be regulated by different signaling pathways with 
retinoid-, vitamin D- and cytokine-activated cascades 
playing important roles
53.
Cathelicidin LL-37 expression in human keratinocytes is 
regulated by the vitamin D pathway
54. This could explain 
why rosacea occurs mainly in the face as exposition to 
ultraviolet (UV) light triggers activation of vitamin D in 
keratinocytes and subsequent cathelicidin expression
54,55.
Recently, a second - vitamin D independent - pathway 
triggering the induction of cathelicidin synthesis in kera-
tinocytes was identified: In keratinocytes, cathelicidin 
expression increases upon several external stimuli (such as 
infection, injuries, UV irradiation, and permeability barrier 
disruption) which also trigger endoplasmic reticulum (ER) 
stress. Indeed, ER stress increases CAMP expression via 
nuclear factor-κB-carbohydrateresponsive element binding 
proteinα activation independent of vitamin D receptor 
(VDR) activation demonstrating a novel role for ER stress 
in stimulating innate immunity
56. This again could explain 
why rosacea patients often report on unspecific triggers 
(e.g. heat) which would mediate their pro-inflammatory 
activities through ER stress and cathelicidin induction.
But why is the cutaneous protease activity elevated in 
lesional skin in rosacea? As mentioned earlier resident 
cells in the skin such as keratinocytes express receptors 
sensing pathogen associated molecular patterns (PAMPs). 
TLRs are one family of PAMP sensors triggering further 
pro-inflammatory pathways. As an example, ligands for 
TLR2 are microbial structure molecules such as cell wall 
fragments but also chitin
57,58. In involved skin in rosacea 
patients keratinocytes express elevated level of TLR2
57. 
Furthermore, TLR2 activation in keratinocytes leads to a 
higher expression of kallikrein proteases and higher 
protease activity (Fig. 1)
57.
And what is the trigger for TLR2 in rosacea? Demodex 
mites are frequently found on the skin of rosacea patients 
and skin inflammation correlates with mite density
59. 
Possibly, chitin released from these mites could serve as 
the trigger for TLR2 on keratinocytes and link demodex 
with increased protease activity and cathelicidin induced 
inflammation in rosacea (Fig. 1).
Together these observations possibly identify a complex 
pro-inflammatory cascade involving demodex, TLRs, M Reinholz, et al
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cathelicidin and proteases in the pathogenesis of rosacea. 
Nevertheless, several of these mechanisms could be 
exploited for novel therapies to be discussed in the 
following paragraphs.
PSORIASIS
Psoriasis is a third inflammatory skin disease associated 
with abnormal expression and activity of AMPs
60. An 
autoinflammatory reaction is suspected to play a major 
role in the course of the disease however the triggers of 
inflammation in psoriasis remain unknown.
Cathelicidin LL-37 is strongly increased in skin in psoriatic 
plaques and recently LL-37 was identified as a critical 
factor for the activation of an auto-inflammatory cascade 
in psoriasis
61. LL-37 isolated from lesional psoriatic skin 
forms complexes with human self-DNA. These LL-37/ 
self-DNA complexes are sensed by dermal plasmacytoid 
dendritic cells (pDCs) through TLR9
61. In turn, activated 
pDCs secrete large amounts of interferon α to activate 
further T-cell mediated immune responses. Thus, LL-37 
converts inert self-DNA into a potent trigger of interferon 
production by pDCs in psoriatic skin
61.
Subsequently, the capacity of LL-37 to bind to self-DNA 
and influence inflammation prompted further studies in 
psoriasis patients. DNA is not only sensed by TLRs but 
also by absent in melanoma 2 (AIM2), a cytosolic DNA 
receptor which upon activation triggers inflammasome 
activation and IL-1β secretion
62. AIM2 expression and 
IL-1β secretion is high in psoriatic lesions but not in 
healthy skin
62. Furthermore, abundant cytosolic DNA was 
detected in keratinocytes in psoriatic lesions, which 
triggered the release of IL-1β  via the AIM2 infla-
mmasome
62. Again, LL-37 bound cytosolic DNA but this 
time neutralized its pro-inflammatory activity: Cytosolic 
DNA complexed with cathelicidin LL-37 did not activate 
the AIM2 inflammasome and subsequent IL-1β secretion 
was inhibited.
Thus, these studies revealed a contrasting role of 
cathelicidin in self-DNA mediated inflammation in lesional 
skin in psoriasis: While dermal LL-37 binds self-DNA and 
mediates activation of pDCs, epidermal LL-37 complexes 
with cytosolic DNA in keratinocytes and blocks inflam-
masome activation and IL-1β  release. To date it is unclear 
which effect - the pro- or the anti-inflammatory - of 
cathelicidin LL-37 is predominating. Studies in patients 
under treatment could contribute to the understanding of 
the role of LL-37 in psoriasis. These studies will be 
discussed in more detail in the following paragraphs.
HIDRADENITIS SUPPURATIVA
HS is a chronic inflammatory skin disease often resulting 
in exzessive scarring and fistulation. The axillar, gluteal, 
inguinal and genital skin areas are often affected. As the 
pathophysiology of HS is unclear, medical treatment is 
difficult or even frustrating. To date, surgical excision of 
affected skin areas is the treatment of choice. AMPs are 
strongly expression and secreted by the apocrine sweat 
glands, distal hair follicle epithelium, and epidermis in 
HS
63. In particular, immunoreactivity of the cathelicidin 
LL-37 was increased in HS lesions. The pro-inflammatory 
functions of LL-37 could trigger local disease excacer-
bation and thus promote HS development. However, the 
triggers and pathways of AMP regulated innate immunity 
in HS are for the most part unclear and require further 
research work.
CATHELICIDIN AS A NOVEL TARGET FOR 
THERAPEUTIC APPROACHES IN 
INFLAMMATORY SKIN DISEASES
The increasing data on the role of cathelicidin and other 
AMPs in inflammatory skin diseases has prompted the 
idea that through targeting AMP expression cutaneous 
inflammation might be ameliorated. In order to influence 
AMP expression and function the detailed knowledge of 
the mechanisms and pathways regulation AMP expression 
in skin is a prerequisite. As mentioned earlier some 
regulatory pathways have been identified during the past 
years: As an example, vitamin D directly activates cathe-
licidin gene CAMP transcription and LL-37 peptide 
expression in several cell types such as keratinocytes and 
monocytes
64,65. Importantly, increased cathelicidin expre-
ssion is paralleled by increased cathelicidin peptide 
activity
34. Restoring antimicrobial activity or balancing 
“alarming” activities of AMPs could be novel goals of 
topical or systemic treatments for inflammatory skin 
diseases
66.
ATOPIC DERMATITIS
The rate of atopy and in particular the prevalence of AD is 
very high in industrialized countries. As patients with AD 
show structural defects in their cutaneous barrier and 
dysfunction of cutaneous innate immunity leading to 
microbial superinfections restoration of the antimicrobial 
defense shield could be beneficial. Vitamin D directly 
regulates cathelicidin AMP expression in keratinocytes 
and a link between systemic vitamin D serum levels, sun 
exposure and atopy has been discussed
67.Cathelicidin LL-37 and Inflammatory Skin Disease
Vol. 24, No. 2, 2012 131
Indeed, oral supplementation of vitamin D induces cathe-
licidin production in skin in AD patients
68. Also, systemic 
treatment with a VDR agonist leads to healing of 
experimental allergen-triggered eczema possibly through 
effects on the cutaneous barrier
69. Topical vitamin D 
application on human skin also increases cathelicidin 
immunoreactivity
14. Still, to date it is unclear whether AD 
patients treated with vitamin D show a decreased rate of 
infectious complications as a consequence of increased 
cathelicidin expression. 
As mentioned earlier, human skin is able to synthesize 
active vitamin D from precursor molecules under the 
influence of UV irradiation. Even in a culture dish UV-B 
irradiation of human keratinocytes supplemented with 
7-dehydrocholesterol triggers the synthesis of hormonally 
active calcitriol, which then differentially affects expression 
of AMPs cathelicidin and HBD2
55. In a clinical setting, 
UVB phototherapy increases the endogenous production 
of vitamin D in AD patients which is accompanied by 
healing of eczema lesions
70. These effects might be 
mediated by improved vitamin D balance, the local 
cytokine network and/or AMP expression
70. However, 
larger, prospective, multi-center studies are needed to 
clarify the role AMP regulated barrier functions in AD.
ROSACEA
The pathways involved in increased and dysfunctional 
cathelicidin in the skin of patients with rosacea are 
complex. However, due to the multiple regulatory steps 
involved several strategies are possible for topical and 
systemic therapies (Fig. 1).
As an example, chitin released from demodex mites 
possibly triggers TLR2 activation and subsequent protease 
activity in the skin of rosacea patients. Thus, decreasing 
the load of demodex mites on the skin or blocking of 
TLR2 could decrease protease activity and cutaneous 
inflammation. Indeed, inhibition of demodex has been 
suggested in the treatment of rosacea before and decreased 
mite density associates with reduced inflammation in 
clinical studies
71. Retinoids, which are commonly used in 
the treatment of rosacea, block TLR2 activity and could 
mediate their effects through this mechanism as well (Fig. 
1).
The increased protease activity is central to the pro- 
inflammatory effects of dysfunctional cathelicidin peptides 
in rosacea
50. Hence, topical or systemic therapies inhi-
biting pathologic protease activity could exert anti- 
inflammatory effects in rosacea. Indeed, some established 
and clinically effective therapies probably exert their 
beneficial effect through this mechanism. As an example, 
tetracyclines, such as doxycycline, can inhibit proteases 
and ameliorate cutaneous inflammation in rosacea
34,72,73. 
Importantly, these anti-inflammatory effects are independent 
of the antimicrobial effect of e.g. doxycycline and the 
doses needed for clinical effect are probably lower than 
those needed to treat infections (Fig. 1).
Azelaic acid - another topical drug commonly used for 
rosacea
74 - might reduce the protease activity in kera-
tinocytes, too
75.
Another way to interfere with the outlined pro-inflam-
matory cascade could be the blockade of increased 
cathelicidin production in lesional skin in rosacea. As 
mentioned earlier, vitamin D controls the expression of 
cathelicidin and UVB triggers activation of vitamin D from 
precursor molecules
65. Thus, the advice to rosacea 
patients to avoid exposure to sun light might find its 
scientific basis in those observations.
Also, alterations VDR gene have been described in patients 
with severe rosacea (rosacea conglobata) suggesting that 
vitamin D signaling is indeed affecting the pathogenesis of 
rosacea
76. Drugs which interfere with vitamin D signaling 
and therefore are able to control the expression and 
processing of cathelicidins might offer a new approach in 
the management of rosacea
77.
PSORIASIS
As cathelicidin might be a central factor in the patho-
genesis of psoriasis therapies targeting cathelicidin expre-
ssion might influence the course of the disease. On the 
one hand, the blockage of dermal LL-37 or a decrease in 
dermal cathelicidin deposition might interrupt the vicious 
circle of cutaneous inflammation induced by elevated 
levels of LL-37/self-DNA-complexes which leads to pDC 
activation
61,78. On the other hand, increased epidermal 
cathelicidin could lead to sustained AIM2 inflammasome 
inhibition and a decrease in cutaneous inflammasome 
activity.
Expression of cathelicidin in keratinocytes is regulated by 
vitamin D. Moreover, vitamin D analogs have been used 
in the treatment of psoriasis for a long time. However, the 
molecular mechanisms behind their clinical effects were 
not completely lucid. vitamin D analogs bind to the VDR 
followed by binding of the VDR binds to vitamin D 
responsive element in the promoter region of the cathe-
licidin gene
34,66.
Topical treatment with vitamin D analogs, such as calci-
potriol, decrease inflammation and reduce morphological 
changes in psoriatic lesions
79. At the same time calci-
potriol treatment decreases pro-inflammatory cytokines 
but strongly increases the expression of cathelicidin
66. M Reinholz, et al
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Similar to AD, UVB phototherapy is also used for the 
treatment of affected skin in psoriasis vulgaris. Repeated 
treatments of psoriasis patients with narrowband UVB 
significantly decreased skin inflammation in psoriasis 
patients but at the same time strongly increased vitamin D 
serum levels and cutaneous cathelicidin expression
70. 
Thus, established therapies targeting the vitamin D pathway 
reduce inflammation while increasing epidermal catheli-
cidin expression in psoriatic lesions. The anti-inflamma-
tory effect of cathelicidin LL-37 on the AIM2 inflamma-
some pathway could be responsible for this effect.
Vitamin D serum levels can also be increased through oral 
supplementation and some studies have started to 
investigate if the vitamin D serum levels in patients with 
psoriasis correlate with cutaneous AMP expression. One 
study revealed that cathelicidin expression in lesional skin 
was higher in serum vitamin D sufficient groups compared 
to serum vitamin D deficient groups
80. Apparently, vita-
min D serum levels and cathelicidin expression were not 
sufficient to inhibit inflammation. Therefore, more pro-
spective interventional studies testing, whether increasing 
vitamin D serum levels affects the course of psoriasis are 
needed.
CONCLUSIONS AND OUTLOOK
Many inflammatory skin diseases such as AD, psoriasis 
and rosacea are characterized by dysregulated synthesis of 
AMPs. Cathelicidin LL-37 is one important AMP found in 
skin. As cathelicidin exerts antimicrobial but also immune 
functions dysregulated expression and processing of this 
AMP is involved in the pathogenesis of chronic inflamma-
tory skin diseases. As the regulatory mechanisms of cathe-
licidin gene regulation and peptide processing become 
clearer strategies to influence these processes emerge. 
Furthermore, established therapies such as topical and 
systemic treatments for rosacea or psoriasis might mediate 
their effects through their impact on cathelicidin. Further 
research could identify novel targets and mechanisms, 
which could lead to innovative treatments for inflamma-
tory skin diseases, through their effects on cathelicidin.
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